A phase II, multicentre, double-blind, randomised, placebo-controlled study on efficacy and tolerability of Rifaximin vaginal tablets in the treatment of bacterial vaginosis.
Latest Information Update: 05 Jun 2013
At a glance
- Drugs Rifaximin (Primary)
- Indications Bacterial infections; Bacterial vaginosis
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms VARIANT 1
- Sponsors Alfa Wassermann SpA
- 21 Apr 2012 Additional location (Germany) added as reported by European Clinical Trials Database record.
- 15 Jun 2011 New trial record